Clinical Trials Logo
  1. Home
  2. CVD
  3. NCT01163604

Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting — APORIAS  

CVD Clinical Trial

Official title:
Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

Clinical Trial Summary

Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis post cranial stenting. This study will test the safety and efficacy of the argatroban on prevent occlusion and restenosis in patients with intracranial and extracranial artery stenting.

Clinical Trial Description

The risk of restenosis post intracranial and extracranial artery stenting is 20-40%, therefore, in the past, aspirin and clopidogrel were performed as anticoagulant therapy post stenting.But this treatment had limited effectiveness upon restenosis. Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis post cranial stenting. This study will test the safety and efficacy of the argatroban on prevent occlusion and restenosis in patients with intracranial and extracranial artery stenting. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01163604
Study type Interventional
Source Jinling Hospital, China
Contact
Status Completed
Phase Phase 4
Start date August 2010
Completion date August 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02480504 - Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Active, not recruiting NCT00038727 - Diabetes Prevention Program Outcomes Study Phase 3
Completed NCT03967678 - Omega (n)-3 PUFA Enriched Beef & Health Outcomes. N/A
Completed NCT01251302 - Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Not yet recruiting NCT05716659 - EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
Withdrawn NCT02158754 - Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
Completed NCT01077388 - e-Care for Heart Wellness Phase 3
Completed NCT04384029 - The Geneva Covid-19 CVD Study
Active, not recruiting NCT02382822 - Copenhagen Co-morbidity in HIV Infection Study
Active, not recruiting NCT01825668 - Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy N/A
Completed NCT02223286 - Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making N/A
Completed NCT00289237 - Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease N/A
Not yet recruiting NCT03658031 - Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction Phase 3
Completed NCT03636529 - Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes N/A
Completed NCT00500617 - Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
Completed NCT00500708 - Diagnostic Investigation of Sudden Cardiac Event Risk N/A
Completed NCT01255852 - Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting Phase 4
Completed NCT00583297 - Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial N/A